IRB #

STUDY00018966

Title

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

Principal Investigator

Uma Borate

Study Purpose

The purpose of this study is to compare the effects of the study drug with a placebo (identical looking tablet containing no medication) to learn how well the study drug works in combination with standard chemotherapy for treating patients with acute myeloid leukemia (AML).

Medical Condition(s)

Acute Myeloid Leukemia

Eligibility Criteria

-Age 18 or older
-You have untreated Acute Myeloid Leukemia

Age Range

18 - N/A

Healthy Volunteers Needed

No

Duration of Participation

Your investigator will decide how long you will receive study treatment , depending on how well your leukemia responds to study treatment. The number of visits you will need to make to the clinic will depend on how long you continue study treatment. Following the study treatment period, you will enter the follow-up phase of the study for at least 5 years or until the study is complete.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Pfizer Inc.

Recruitment End

01/01/2028

Compensation Provided

No


Go Back